Clinical PET and PET/CT PETCT PRE(I-X).Qxd 23/10/04 11:19 AM Page Iii

Total Page:16

File Type:pdf, Size:1020Kb

Clinical PET and PET/CT PETCT PRE(I-X).Qxd 23/10/04 11:19 AM Page Iii PETCT_PRE(i-x).qxd 23/10/04 11:19 AM Page i Clinical PET and PET/CT PETCT_PRE(i-x).qxd 23/10/04 11:19 AM Page iii Clinical PET and PET/CT With 145 Figures H. JADVAR, MD, PhD, FACNM Assistant Professor of Radiology and Biomedical Engineering, Keck School of Medicine, University of Southern California, Loa Angeles, CA, USA, and Visiting Associate in Bioengineering, California Institute of Technology, Pasadena, CA, USA J.A. PARKER Associate Professor of Radiology, Department of Radiology, Harvard Medical School, Boston, Massachusetts, USA PETCT_PRE(i-x).qxd 23/10/04 11:19 AM Page iv H. Jadvar, MD, PhD Assistant Professor of Radiology and Biomedical Engineering, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA, and Visiting Associate in Bioengineering, California Institute of Technology, Pasadena, CA, USA J.A. Parker, MD, PhD Associate Professor of Radiology, Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library Library of Congress Cataloging-in-Publication Data Jadvar, H. Clinical PET and PET/CT / H. Jadvar and J.A. Parker. p. ; cm. Includes bibliographical references and index. ISBN 1-85233-838-5 (alk. paper) 1. Tomography. 2. Tomography, Emission. I. Parker, J. Anthony. II. Title. [DNLM: 1. Tomography, Emission-Computed–methods. 2. Tomography, X-Ray Computed–methods. WN 206 J21c 2005] RC78.7.T6.J346 2005 616.07′57–dc22 2004058913 Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patents Act 1988, this publication may only be reproduced, stored or transmitted, in any form or by any means, with the prior permission in writing of the publishers, or in the case of reprographic reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency. Enquiries concerning reproduction outside those terms should be sent to the publishers. ISBN 1-85233-838-5 Springer London Berlin Heidelberg Springer Science+Business Media springeronline.com © Springer-Verlag London Limited 2005 The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore free for general use. Product liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature. Typeset by EXPO Holdings Sdn Bhd Printed and bound in the United States of America 28/3830-543210 Printed on acid-free paper SPIN 10950500 PETCT_PRE(i-x).qxd 23/10/04 11:19 AM Page v Table of Contents Foreword ............................................................................................................vii Preface ................................................................................................................ix 1. PET Physics and Instrumentation ..............................................................1 2. PET Radiotracers........................................................................................45 3. Cardiology ..................................................................................................69 4. Neurology and Psychiatry..........................................................................87 5. Oncology—Brain ......................................................................................97 6. Oncology—Head, Neck and Thyroid......................................................103 7. Oncology—Lungs ....................................................................................117 8. Oncology—Digestive Tract......................................................................137 9. Oncology—Pancreas and Hepatobiliary System ....................................153 10. Oncology—Breast and Female Reproductive System ............................161 11. Oncology—Male Reproductive System ..................................................181 12. Oncology—Urology ................................................................................189 13. Oncology—Bone and Soft Tissue Tumors..............................................195 14. Oncology—Lymphoma ..........................................................................205 15. Oncology—Melanoma ............................................................................227 16. Infection and Inflammation ....................................................................235 17. Pediatrics ..................................................................................................243 18. Variants and Pitfalls..................................................................................255 Index ................................................................................................................269 Table of Contents v PETCT_PRE(i-x).qxd 10/11/04 9:06 AM Page vii Foreword: Imaging Marches Forward The field of molecular imaging/nuclear medicine continues to build excitement for the medical community as a whole. To be able to visualize fundamental molecular and biochemical processes in patients in a meaningful way has truly become reality. Of all the available molecular probes and tools it is clear that FDG with PET-CT is one of the true clinical success stories. Very few would have been able to predict the eventual impact of a simple glucose analog as a marker for imaging cancer, hibernating myocardium, Alzheimer’s disease, epilepsy and many other important disease processes. Although relatively well entrenched in the imaging research community there is a growing need to better explain the use of FDG in everyday clinical applications. As more radiol- ogists become involved in the daily interpretation of FDG PET-CT scans, it is important that they understand this technology. With the continued expansion of reimbursement for FDG PET it is important to point out both the advan- tages and limitations of this technology in the routine management of patients. This book is a concise summary of the use of FDG PET/PET-CT for the practicing Radiologist/Nuclear Medicine Physician. In this regard it fills an important void of being relevant to the clinical imaging community with an emphasis on the practical utility of FDG across many areas including oncology. The consistency between chapters and the highly relevant clinical examples make this book a true pleasure to read. The use of figures with both anatomical and functional information truly helps to make case presentations very clear. The specific attention to pediatric FDG PET-CT is also particularly a refreshing welcome. Drs. Jadvar and Parker have done a wonderful job in putting together a textbook that is clear, concise and timely. I hope the readers will find it a useful resource for becoming state-of-art practitioners in the rapidly growing and exciting field of FDG PET-CT. Sanjiv Sam Gambhir M.D., Ph.D. Director, Molecular Imaging Program at Stanford Head, Nuclear Medicine Professor of Radiology & Bio-X Stanford University Stanford, California, USA Foreword vii PETCT_PRE(i-x).qxd 23/10/04 11:19 AM Page ix Preface Medical imaging has undergone remarkable evolution over the past century. Since the discovery of the x-rays by Wilhelm Röntgen, for which he received the Nobel Prize in 1901, there have been many other important discoveries and technical developments that have culminated in our current sophisticated multi-modality imaging systems. Nobel Prizes have been given for the discov- eries of radioactivity (Marie Curie, Pierre Curie, and Henri Becquerel in 1903) and the positron (Carl Anderson in 1936) and for technical developments such as the radiotracer concept (George De Hevesy in 1943), computed tomography (Godfrey Hounsfield and Alan Cormack in 1979), and magnetic resonance imaging (Paul Lauterbur and Peter Mansfield in 2003). In keeping pace with these milestones in the evolution of medical imaging, positron emission tomography (PET), and more recently integrated positron emission tomography-computed tomography (PET-CT), have now emerged not only as important research tools but also as significant diagnostic imaging systems in clinical medicine. There is little doubt that in the near future PET and PET-CT will become even more important as clinical imaging tools for the evaluation of many disease processes. PET and PET-CT will also aid in the evo- lution from the current nonspecific imaging methods toward patient-specific imaging evaluation based on morphologic, physiologic, molecular, and genetic markers of disease. Ultimately, the use of multi-modality imaging systems and “smart” specific imaging agents will achieve the key tasks of accurate diagnosis, treatment evaluation, surveillance, and prognosis in individual patients. Toward this goal, we have attempted to compile a relatively short book that reviews the current state of affairs for PET and PET-CT. Each chapter of the book is intended to be independent, so that a reader may refer to any particu- lar chapter of interest without loss of continuity. Therefore, some repetitions of concepts may be noted. Another difference from other books is that instead of referring to various sources by a reference number in the text, we list all the ref- erences alphabetically in the bibliography of each chapter and no specific refer- rals
Recommended publications
  • [Product Monograph Template
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Kinevac® (Sincalide) For Injection 5 mcg/vial Diagnostic Cholecystokinetic Bracco Imaging Canada Date of Initial Approval: Montreal, Quebec July 2, 1996 Canada, H1J 2Z4 Date of Revision: October 30, 2019 Submission Control No: 231066 Product Monograph Kinevac® Page 1 of 14 TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................. 3 1 INDICATIONS ................................................................................................................. 3 Pediatrics ........................................................................................................................ 3 Geriatrics ......................................................................................................................... 3 2 CONTRAINDICATIONS .................................................................................................. 3 3 DOSAGE AND ADMINISTRATION ................................................................................ 4 Recommended Dose and Dosage Adjustment ................................................................ 4 Reconstitution .................................................................................................................. 4 4 OVERDOSAGE ..............................................................................................................
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • 207/2015 3 Lääkeluettelon Aineet, Liite 1. Ämnena I Läkemedelsförteckningen, Bilaga 1
    207/2015 3 LÄÄKELUETTELON AINEET, LIITE 1. ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN, BILAGA 1. Latinankielinen nimi, Suomenkielinen nimi, Ruotsinkielinen nimi, Englanninkielinen nimi, Latinskt namn Finskt namn Svenskt namn Engelskt namn (N)-Hydroxy- (N)-Hydroksietyyli- (N)-Hydroxietyl- (N)-Hydroxyethyl- aethylprometazinum prometatsiini prometazin promethazine 2,4-Dichlorbenzyl- 2,4-Diklooribentsyyli- 2,4-Diklorbensylalkohol 2,4-Dichlorobenzyl alcoholum alkoholi alcohol 2-Isopropoxyphenyl-N- 2-Isopropoksifenyyli-N- 2-Isopropoxifenyl-N- 2-Isopropoxyphenyl-N- methylcarbamas metyylikarbamaatti metylkarbamat methylcarbamate 4-Dimethyl- ami- 4-Dimetyyliaminofenoli 4-Dimetylaminofenol 4-Dimethylaminophenol nophenolum Abacavirum Abakaviiri Abakavir Abacavir Abarelixum Abareliksi Abarelix Abarelix Abataceptum Abatasepti Abatacept Abatacept Abciximabum Absiksimabi Absiximab Abciximab Abirateronum Abirateroni Abirateron Abiraterone Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoni natrium Acediasulfon natrium Acediasulfone sodium Acenocoumarolum Asenokumaroli Acenokumarol Acenocumarol Acepromazinum Asepromatsiini Acepromazin Acepromazine Acetarsolum Asetarsoli Acetarsol Acetarsol Acetazolamidum Asetatsoliamidi Acetazolamid Acetazolamide Acetohexamidum Asetoheksamidi Acetohexamid Acetohexamide Acetophenazinum Asetofenatsiini Acetofenazin Acetophenazine Acetphenolisatinum Asetofenoli-isatiini
    [Show full text]
  • Chapter 12 Monographs of 99Mtc Pharmaceuticals 12
    Chapter 12 Monographs of 99mTc Pharmaceuticals 12 12.1 99mTc-Pertechnetate I. Zolle and P.O. Bremer Chemical name Chemical structure Sodium pertechnetate Sodium pertechnetate 99mTc injection (fission) (Ph. Eur.) Technetium Tc 99m pertechnetate injection (USP) 99m ± Pertechnetate anion ( TcO4) 99mTc(VII)-Na-pertechnetate Physical characteristics Commercial products Ec=140.5 keV (IT) 99Mo/99mTc generator: T1/2 =6.02 h GE Healthcare Bristol-Myers Squibb Mallinckrodt/Tyco Preparation Sodium pertechnetate 99mTc is eluted from an approved 99Mo/99mTc generator with ster- ile, isotonic saline. Generator systems differ; therefore, elution should be performed ac- cording to the manual provided by the manufacturer. Aseptic conditions have to be maintained throughout the operation, keeping the elution needle sterile. The total eluted activity and volume are recorded at the time of elution. The resulting 99mTc ac- tivity concentration depends on the elution volume. Sodium pertechnetate 99mTc is a clear, colorless solution for intravenous injection. The pH value is 4.0±8.0 (Ph. Eur.). Description of Eluate 99mTc eluate is described in the European Pharmacopeia in two specific monographs de- pending on the method of preparation of the parent radionuclide 99Mo, which is generally isolated from fission products (Monograph 124) (Council of Europe 2005a), or produced by neutron activation of metallic 98Mo-oxide (Monograph 283) (Council of Europe 2005b). Sodium pertechnetate 99mTc injection solution satisfies the general requirements of parenteral preparations stated in the European Pharmacopeia (Council of Europe 2004). The specific activity of 99mTc-pertechnetate is not stated in the Pharmacopeia; however, it is recommended that the eluate is obtained from a generator that is eluted regularly, 174 12.1 99mTc-Pertechnetate every 24 h.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,803,046 B2 Metcalfe Et Al
    USOO6803046B2 (12) United States Patent (10) Patent No.: US 6,803,046 B2 Metcalfe et al. (45) Date of Patent: Oct. 12, 2004 (54) SINCALIDE FORMULATIONS OTHER PUBLICATIONS (75) Inventors: Edmund C. Metcalfe, Hillsborough, NJ Sitzmann, et al., “Cholecystokinin Prevents Parenteral (US); Jo Anna Monteferrante, Raritan Nutrition Induced Biliary Sludge in Humans.” Surgery, Township, NJ (US); Margaret Gynecology & Obstetrics, vol. 170, Jan. 1990, pp. 25-31. Newborn, Hamilton Township, NJ Teitelbaum et al., “Treatment of Parenteral Nutrition-ASSo (US); Irene Ropiak, Lawrenceville, NJ ciated Cholestasis with Cholecystokinin-Octapeptide,” (US); Ernst Schramm, North Journal of Pediatric Surgery, vol. 30, No. 7, Jul. 1995, pp. Brunswick, NJ (US); Gregory W. 1082-1085. White, Monmouth Junction, NJ (US); Moss and Amii, “New Approaches to Understanding the Julius P. Zodda, Mercerville, NJ (US) Etiology and Treatment of Total Parenteral Nutrition-ASSo ciated Cholestasis,” Seminars in Pediatric Surgery, vol. 8, (73) Assignee: Bracco International B.V., Amsterdam No. 3, Aug. 1999, pp. 140–147. (NL) Teitelbaum, "Parenteral Nutrition-ASSociated Cholestasis,” c: - Current Opinion in Pediatrics, vol. 9, 1997, pp. 270–275. (*) Notice: Subject to any State the SME, tly Teitelbaum and Tracy, “Parenteral Nutrition-Associated patent is extended or adjusted under Cholestasis,” Seminars in Pediatric Surgery, vol. 10, No. 2, U.S.C. 154(b) by 0 days. May 2001, pp. 72–80. Strickley, “Parenteral Formulations of Small Molecules (21) Appl. No.: 10/222,540 Therapeutics Marketed in the United States (1999) -Part (22) Filed: Aug. 16, 2002 1, PDA Journal of Pharmaceutical Science & Technology, e - Vs vol. 53, No. 6, Nov.-Dec. 1999, pp.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Drugs and Biologicals Fee Schedule
    Payment Allowance Limits for PEIA Effective January 1, 2013 through December 31, 2013 The absence or presence of a HCPCS code does not indicate PEIA coverage. Similarily, the inclusion of a payment limit does not indicate coverage by PEIA. processing the claim. Vaccine Infusion DME Infusion Blood Clotting HCPCS Code Short Description HCPCS Code Dosage Payment Limit AWP% Vaccine Limit AWP% Limit AWP% Blood limit Factor Notes 90371 Hep b ig, im 1 ML$ 104.73 90375 Rabies ig, im/sc 150 IU$ 206.47 90376 Rabies ig, heat treated 150 IU$ 197.46 90385 Rh ig, minidose, im 50 MCG$ 24.62 90585 Bcg vaccine, percut 50 MG$ 120.87 90586 Bcg vaccine, intravesical 1 EACH$ 120.87 90632 Hep a vaccine, adult im 1 ML$ 50.93 90654 Flu vaccine, intradermal, no preserv 0.1 ML$ 18.98 95 18.981 90655 Flu vaccine no preserv 6-35m, im 0.25 ML$ 16.46 95 16.456 90656 Flu vaccine no preserv 3 yo & >, im 0.50 ML$ 12.40 95 12.398 90657 Flu vaccine, 6-35 mo, im 0.25 ML$ 6.02 95 6.023 90660 Flu vaccine, nasal 0.2 ML$ 23.46 95 23.456 90662 Flu vacc prsv free inc antig 0.5 ML$ 30.92 95 30.923 90669 Pneumococcal vacc, 7 val im 0.5 ML$ 95.48 95 95.481 90670 Pneumococcal vacc, 13 val im 0.5 ML$ 137.03 95 137.028 90675 Rabies vaccine, im 1 ML$ 190.40 90691 Typhoid vaccine, im 0.5 ML$ 68.27 90703 Tetanus vaccine, im 0.5 ML$ 35.41 90714 Td vaccine no prsrv >/= 7 yo, im 0.5 ML$ 19.93 90715 Tdap => 7 yo, im 0.5 ML$ 33.35 90717 Yellow fever vaccine, sc 0.5 ML$ 71.49 90732 Pneumococcal vaccine 0.5 ML$ 65.77 95 65.774 90733 Meningococcal vaccine, sc 0.5 ML$ 106.49 90735 Encephalitis
    [Show full text]
  • 1 Zkoumadla ANGLICKO–ČESKÁ 2016 Acetic Acid, Dilute R1
    7.4.2016 Zkoumadla ANGLICKO–ČESKÁ 2016 Vysvětlivky Times New Roman bold – název nového nebo změněného zkoumadla v ČL 2009 – Dopl. 2016, názvy označené N, jsou pro zkoumadla použitá v národních článcích Anglický název Český název Acacia Arabská klovatina R Acacia solution Arabská klovatina RS Acebutolol hydrochloride Acebutolol-hydrochlorid R Acetal Acetal R Acetaldehyde Acetaldehyd R Acetaldehyde ammonia trimer trihydrate Acetaldehyd-amoniak trimer trihydrát R Acetic acid, anhydrous Kyselina octová bezvodá R Acetic acid, glacial Kyselina octová ledová R Acetic acid Kyselina octová RS Acetic acid, dilute Kyselina octová zředěná RS Acetic acid, dilute R1 Kyselina octová zředěná RS1 Acetic anhydride Acetanhydrid R Acetic anhydride solution R1 Acetanhydrid RS1 Acetic anhydride-sulfuric acid solution Acetanhydrid v kyselině sírové RS Acetone Aceton R Acetonitrile Acetonitril R Acetonitrile for chromatography Acetonitril pro chromatografii R Acetonitrile R1 Acetonitril R1 Acetoxyvalerenic acid Kyselina acetoxyvalerenová R Acetylacetamide Acetylacetamid R Acetylacetone Acetylaceton R Acetylacetone reagent R1 Acetylaceton RS1 Acetylacetone reagent R2 Acetylaceton RS2 N-Acetyl-ε-caprolactam N-Acetyl-ε-kaprolaktam R Acetyl chloride Acetylchlorid R Acetylcholine chloride Acetylcholin-chlorid R Acetyleugenol Acetyleugenol R N-Acetylglucosamine N-Acetylglukosamin R Acetyl-11-keto-β-boswellic acid Kyselina acetyl-11-keto-β-boswellová R N-Acetylneuraminic acid Kyselina N-acetylneuraminová R N-Acetyltryptophan N-Acetyltryptofan Acetyltyrosine ethyl ester
    [Show full text]
  • Foi-276-1213-02.Pdf
    Application Date Application Drug Name Generic Drug Name Indication Status Approved neovascular age-related macular degeneration (AMD) as per the Novartis Lucentis ranibizumab APPROVED 27/11/2012 Pharmaceuticals Australia Pty Ltd protocol cholecalciferol moderate to severe Vitamin D deficiency APPROVED 2/07/2012 Cholecystokinin for imaging of the biliary tract APPROVED 12/09/2011 cholecystokinin Kinevac/ Sincalide imaging of the biliary tract APPROVED 12/09/2011 cholecystokinin Kinevac/ Sincalide for use in nuclear medicine biliary studies APPROVED 12/09/2011 Melatonin sleep disturbance in children with severe disabilities APPROVED 25/08/2011 Indocyanine Green retinal angiography APPROVED 13/09/2011 Cholecystokinin Sincalide, Kinevac for imaging of the biliary tract. APPROVED 13/09/2011 cholecystekinin Kinevac/ Sincalide use in imaging of the biliary tract APPROVED 13/09/2011 during vitreo-retinal surgery and for intravenous injection to perform ICG Indocyanine Green APPROVED 12/09/2011 angiography during vitreo-retinal surgery and for intravenous injection to perform ICG Indocyanine Green APPROVED 12/09/2011 angiography. during vitreo-retinal suegery and for intravenous injection to perform ICG Indocyanine Green APPROVED 12/09/2011 angiography during vitreo-retinal surgery and for intravenous injection to perform ICG Indocyanine Green APPROVED 8/11/2011 angiography. Cholecystokinin Sincalide, Kinevac for nuclear medicine biliary studies. APPROVED 14/11/2011 Mafenide 5% Sulfamylon for wound management of deep partial and full thickness
    [Show full text]
  • Drugs Used As Interventional Agents in Nuclear Medicine
    THE UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER COLLEGE OF PHARMACY ALBUQUERQUE, NEW MEXICO The University of New Mexico Correspondence Continuing Education Courses for Nuclear Pharmacists and Nuclear Medicine Professionals VOLUMEVII, NUMBER2 Drugs Used as Interventional Agents in Nuclear Medicine by: Vivian S.bveless, PharmD, RPh, BCNP o The Univemi~ of New Mexico Health Sciencw Center Collcg. of ~armacy is mpprovd by the American Council on Pharmaceutical Wucation ~ a provider m@ of continuing pharmaceutical ducacion. Program No. 039-000-98-001 -HM. 2,5 Contnct Hours or .25 CWS Coorditi”ng Wifor and Director of Phrmacy Co&”nuing Educ&”on William B. Hladik III, MS, RPh College of Pharmacy University of New Mexico Health Sciences Center Assoctie ~tior and Production Spectitit Sharon 1. Magers Ramirez, Administrative Assistant II College of Pharmacy University of New Mexico Health Sciences Center Witotial Board George H Hinkle, MS, RPh, BCNP William B. Hladik III, MS, RPh Jeffrey P. Norenbtirg, MS, RPh, BCNP Laura L. Boles Ponto, PhD, RPh Timothy M. Quinton, PharmD, MS, RPh, BCNP Guwt Reviewer Sam C. Augustine, PharmD, RPh, BCNP While the advice and information in thi~ publication are believd to be true and accurate at press time, neither the author(s) nor the editor nor the publisher can accept any legat responsibility for my errom or omissions tbt may be made. Thc publisher makes no warranty, express or implied, with res~t to the material contained herein. Copyright 1998 University of New Mexico Health Sciences Center Pharmacy Continuing Hucation Albuquerque, New Mexico DRUGS USED AS INTERVENTIONAL AGENTS IN NUCLEAR MEDICINE STATEMENT OF OBJECTIVES The primary purpose of this lesson is to provide a basic understanding of drugs used as interventional agents in the practice of nuclear medicine.
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • ( N Am Am Pm Vpm 17 16
    US 20090202635A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0202635 A1 Scott (43) Pub. Date: Aug. 13, 2009 (54) DELIVERY SYSTEM, APPLICATION, AND Publication Classification METHOD (51) Int. Cl. (76) Inventor: Stephen Michael Scott, Tampa, FL A6IR 9/12 (2006.01) (US) A69/20 (2006.01) Correspondence Address: STEPHEN M. SCOTT (52) U.S. Cl. ............................ 424/468; 424/464; 424/45 515 BOSPHORUS AVE TAMPA, FL 33606 (US) (21) Appl. No.: 12/361,863 (57) ABSTRACT (22) Filed: Jan. 29, 2009 A sequenced biologically compatible delivery system, appli cation, and method is provided, which increases therapeutic Related U.S. Application Data care of animals by conveniently and effectively Supplying (60) Provisional application No. 61/027,265, filed on Feb. meticulous administration plans requiring sequential admin 8, 2008. istration of varying biologically active agents. 14 15 1 O 16 22 ( N AM AM PM VPM 17 16 88: SH: 8 21 2O 9 Patent Application Publication Aug. 13, 2009 Sheet 1 of 10 US 2009/0202635 A1 ( N AM AM PM VPM II 88: 888 21 2 O 9 Patent Application Publication Aug. 13, 2009 Sheet 2 of 10 US 2009/0202635 A1 F.G. 2A FIG. 2C-2G 30.3 32 3334 3. |Niles (III OOOOOOOss 'eofooooo.OOOOOOO 4 O 36 3. Coolooloo 38 37 3 O FIG. 2B 3. FIG. IIC Patent Application Publication Aug. 13, 2009 Sheet 3 of 10 US 2009/0202635 A1 FIG. 38 37 43 30 FIG. 2G Patent Application Publication Aug. 13, 2009 Sheet 4 of 10 US 2009/0202635 A1 FIG.
    [Show full text]